Evora Biosciences develops EVOGEX, a proprietary therapeutic discovery platform for exosome-based treatments.

Our off-the-shelf exosomes are engineered for improved efficacy, and we aim to disrupt the field of regenerative medicine and beyond.

Evora Bioscience heralded as one of France’s top 15 biotechs to invest in.
Challenges Magazine – March 2022

EVOGEX is Evora’s proprietary therapeutic discovery platform, based on patent-protected engineering of exosomes.

The aim of EVOGEX is to significantly enhance key properties of exosomes, to improve efficacy of exosome-based therapeutic approaches, in regenerative medicine and beyond.

Primary target : digestive fistula healing

Digestive fistula can be life-impairing for patients, and are linked to a variety of conditions, such as Crohn’s Disease, or surgical procedures, such as weight-loss procedures like sleeve gastrectomies.

For complex cases, currently available therapeutic options for patients and clinicians are unsatisfactory. Our lead product EVOGEX-Digest aims to dramatically improve patient outcomes in several GI-related indications.

EVOGEX-Digest stems from world class research in copolymer gels and exosomes, from CNRS and Paris University laboratories.

Exosomes : the next step in regenerative cell therapy medicine

Exosomes are small biological particle secreted by cells, from which they inherit some key therapeutic properties. Stem-cells derived exosomes, in particular, are able to virtually replicate the regenerative properties of their parent cells, while drastically simplifying logistics.

Compared to stem cells, exosome-based treatments offer simpler and more cost-efficient logistics, and greater ease of use for clinicians.

For patients, research has shown that exosomes have a more advantageous risk profile compared to stem cells : no donor rejection, no proliferation or differentiation risks.